Drug Information for Sandostatin LAR Depot (octreotide acetate for injectable suspension) (Novartis Pharmaceuticals Corporation): 1  INDICATIONS AND USAGE

  • Sandostatin LAR Depot 10 mg, 20 mg and 30 mg is indicated in patients in whom initial treatment with Sandostatin Injection has been shown to be effective and tolerated.

  • 1.1 Acromegaly

  • Long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal [see Clinical Studies (14) and Dosage and Administration (2)].

  • 1.2 Carcinoid Tumors

  • Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.

  • 1.3 Vasoactive Intestinal Peptide Tumors (VIPomas)

  • Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors.

  • 1.4 Important Limitations of Use

  • In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth and development of metastases, has not been determined.

  • Drug Information Provided by National Library of Medicine (NLM).